Actinium Pharmaceuticals
ATNM
42 hedge funds and large institutions have $7.11M invested in Actinium Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 15 increasing their positions, 4 reducing their positions, and 8 closing their positions.
2,471% more call options, than puts
Call options by funds: $180K | Put options by funds: $7K
275% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 4
1% more capital invested
Capital invested by funds: $7.05M → $7.11M (+$63K)
0% more funds holding
Funds holding: 42 → 42 (0)
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
0.04% less ownership
Funds ownership: 0.33% → 0.29% (-0.04%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$747K |
| 2 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$565K |
| 3 |
PCM
Prelude Capital Management
New York
|
+$369K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$114K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$105K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DAM
DLD Asset Management
New York
|
-$1.35M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$839K |
| 3 |
SCM
Sio Capital Management
New York
|
-$558K |
| 4 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$200K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$62.1K |
ATNM Hedge Fund Activity: Q3 2018 in Review
42 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q3 2018, worth a combined $7.11M — up 0.89% from $7.05M a quarter earlier.
Fund positioning in ATNM was balanced in Q3 2018: 8 funds opened new positions, 8 closed out, 15 added to existing stakes and 4 trimmed.
The largest buyer was Essex Investment Management, opening a new position worth an estimated $747K. The largest seller was DLD Asset Management, cutting an estimated $1.35M.
- 42 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q3 2018, unchanged from Q2 2018.
- Funds reported $7.11M of Actinium Pharmaceuticals stock for Q3 2018, up 0.89% quarter-over-quarter.
- 8 funds opened new Actinium Pharmaceuticals positions in Q3 2018 and 8 closed out, a net change of 0 holders.
- The largest Actinium Pharmaceuticals buyer in Q3 2018 was Essex Investment Management, an estimated $747K added.
- The largest Actinium Pharmaceuticals seller in Q3 2018 was DLD Asset Management, an estimated $1.35M sold.
Based on aggregated 13F filings for Q3 2018.